Scientific Presentations
Early Decreases in KRAS Mutant Allele Frequency (MAF) Predict Clinical Benefit to the PLK1 Inhibitor
The PLK Inhibitor Onvansertib Overcomes irinotecan Resistance in the RAS-Mutated Metastatic Colorectal Cancer (mCRC) in Vivo and in Patients
Biomarkers of Response to Abiraterone and the Polo-Like Kinase 1 (PLK1) Inhibitor Onvansertib in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients
Combining PARP inhibition with the Polo-like kinase (PLK1) inhibitoronvansertib overcomes PARP inhibitor resistance
A Phase 2 Study of Onvansertib in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1b/2 Trial of the PLK1 Inhibitor Onvansertib in Combination with FOLFIRI-bev in 2L Treatment of KRAS-Mutated Metastatic Colorectal Carcinoma (mCRC)
Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer
The Selective Polo-like Kinase (Plk1) Inhibitor Onvansertib and the Antiandrogen Abiraterone Synergistically Kill Cancer Cells Through Disruption of Mitosis Independently of Androgen Receptor Signaling
A Phase 2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1b/2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of KRAS-Mutated Metastatic Colorectal Cancer
Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2 Study of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Abiraterone in Patients with Abiraterone-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1b/2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of KRAS-Mutated Metastatic Colorectal Cancer
Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1b/2 Study of the Polo-like Kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)